Evidence map›Paper›PMID 34159277›Full record

ArticleHeliyon2021

In vitro inhibitory activity against HPV of the monoterpenoid zinc tetra-ascorbo-camphorate.

Ralph Sydney Mboumba Bouassa, Bernard Gombert, Gabin Mwande-Maguene, Aurèle Mannarini, Laurent Bélec

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06672653 (PREPAP Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06672653 phase1 / phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit

TypeinterventionalSponsorMGB PharmaRan2024 to 2025Enrolled66ConditionsHPV-induced Cancers, HPV Infections, HIV, Cervical CancersArmsThe monoterpenoid zinc tetra-ascorbo-camphorate ("C14"), Distilled water group
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ralph Sydney Mboumba BouassaEcole Doctorale Régionale d'Infectiologie Tropicale de Franceville, BP: 246, Franceville, Gabon.
Bernard GombertMGB Pharma, 30900, Nîmes, France.
Gabin Mwande-MagueneFaculté de Sciences, Département de Chimie et Biochimie, Université des Sciences et Techniques de Masuku (USTM), BP: 901, Franceville, Gabon.
Aurèle MannariniMGB Pharma, 30900, Nîmes, France.
Laurent BélecLaboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015, Paris, France.
Délégation Paris 5 · FRUniversité des Sciences et Techniques de Masuku · GA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zinc tetra-ascorbo-camphorate (or drug "C14") is a synthetic monoterpenoid derivative that has potent anti-HIV-1 activity in vitro. In this study, we evaluated the in vitro antiviral properties of C14 against human papillomavirus (HPV). Inhibition assay of HPV-16-pseudovirus (PsVs) adsorption on COS-7 cells by C14 was used. C14 inhibited HPV-16-PsVs adsorption with IC

Indexed as

Camphor derivatesHPVHPV-16Inhibition assayL-ascorbic acid conjugatePseudovirusTerpenoidZn metal

Identifiers

PMID34159277
PMCPMC8203719
OpenAlexW3167853298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.